18.00 USD
-0.50
2.70%
At close Feb 21, 4:00 PM EST
After hours
13.46
-4.54
25.22%
1 day
-2.70%
5 days
-0.99%
1 month
-5.11%
3 months
37.40%
6 months
39.32%
Year to date
9.76%
1 year
73.08%
5 years
22.45%
10 years
462.50%
 

About: Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.

Employees: 428

0
Funds holding %
of 7,139 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

14,300% more call options, than puts

Call options by funds: $2.59M | Put options by funds: $18K

100% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 17

25% more funds holding in top 10

Funds holding in top 10: 4 [Q3] → 5 (+1) [Q4]

14% more capital invested

Capital invested by funds: $518M [Q3] → $591M (+$73.3M) [Q4]

10% more funds holding

Funds holding: 157 [Q3] → 172 (+15) [Q4]

2.78% less ownership

Funds ownership: 84.24% [Q3] → 81.46% (-2.78%) [Q4]

32% less repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 66

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$22
22%
upside
Avg. target
$22
22%
upside
High target
$22
22%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Canaccord Genuity
Caitlin Cronin
67% 1-year accuracy
8 / 12 met price target
22%upside
$22
Buy
Maintained
3 Feb 2025

Financial journalist opinion

Neutral
GlobeNewsWire
1 week ago
Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025
ALACHUA, Fla. and TAMPA, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2024 fourth quarter and full year financial results on Tuesday, February 25, 2025, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release.
Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025
Positive
Zacks Investment Research
1 month ago
AxoGen, Inc. (AXGN) Soars to 52-Week High, Time to Cash Out?
AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
AxoGen, Inc. (AXGN) Soars to 52-Week High, Time to Cash Out?
Positive
Zacks Investment Research
1 month ago
AxoGen (AXGN) Moves 18.2% Higher: Will This Strength Last?
AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
AxoGen (AXGN) Moves 18.2% Higher: Will This Strength Last?
Neutral
GlobeNewsWire
1 month ago
Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Craig Swandal, experienced medical device manufacturing executive, joins leadership team Craig Swandal, experienced medical device manufacturing executive, joins leadership team
Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Positive
Seeking Alpha
1 month ago
Axogen: Well Placed To Capitalize Growth At Higher Multiples
Axogen has surged 204% in 12 months, driven by strong sales growth, margin expansion, and efficient capital utilization, offering a favorable risk/reward profile.
Axogen: Well Placed To Capitalize Growth At Higher Multiples
Positive
Zacks Investment Research
1 month ago
AxoGen, Inc. (AXGN) Hits Fresh High: Is There Still Room to Run?
AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
AxoGen, Inc. (AXGN) Hits Fresh High: Is There Still Room to Run?
Positive
Zacks Investment Research
2 months ago
Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year?
Here is how AxoGen (AXGN) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year?
Positive
Zacks Investment Research
2 months ago
All You Need to Know About AxoGen (AXGN) Rating Upgrade to Buy
AxoGen (AXGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
All You Need to Know About AxoGen (AXGN) Rating Upgrade to Buy
Positive
Zacks Investment Research
2 months ago
How Much Upside is Left in AxoGen (AXGN)? Wall Street Analysts Think 31.18%
The mean of analysts' price targets for AxoGen (AXGN) points to a 31.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
How Much Upside is Left in AxoGen (AXGN)? Wall Street Analysts Think 31.18%
Neutral
Seeking Alpha
3 months ago
Axogen, Inc (AXGN) Q3 2024 Earnings Call Transcript
Axogen, Inc (NASDAQ:AXGN ) Q3 2024 Results Conference Call November 7, 2024 8:00 AM ET Company Participants Michael Dale - Chairman and Chief Executive Officer Nir Naor - Chief Financial Officer Conference Call Participants Chris Pasquale - Nephron Research Michael Sarcone - Jefferies Caitlin Cronin - Canaccord Genuity Mike Kratky - Leerink Partners Jayson Bedford - Raymond James Ross Osborn - Cantor Fitzgerald Dave Turkaly - Citizens JMP Operator Good morning, everyone. Joining me on today's call is Michael Dale, Axogen's Chief Executive Officer and Director; and Nir Naor, Chief Financial Officer.
Axogen, Inc (AXGN) Q3 2024 Earnings Call Transcript
Charts implemented using Lightweight Charts™